Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Janux Therapeutics, Inc.NASDAQ: JANX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $24.36M (cash outflow) rose 3.6% year over year, behind the +47.3% change in trailing-twelve-month net income. Sequentially, it fell 23.7% from the prior quarter. Over 3 fiscal years it compounded at +21.7% a year.
Context
- Net income amounted to 1136.3% of revenue in FY2025, up 484.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$96.02M (-15.5%) for the fiscal year ending Dec 2026, a slowdown from the +64.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.36M-23.7% QoQ
- Last fiscal yearDec 2025
- -$113.63M+64.7% YoY
- LTMMar 2026
- -$114.48M+47.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.6% | -53.2% | -56.8 pp |
| 1 year | +64.7% | -15.5% | -80.2 pp |
| 3-year CAGR | +21.7% | +25.3% | +3.6 pp |
| 5-year CAGR | +7.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (113.63M) USD
- Year-over-year change
- -64.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (113.63M) | -64.7% |
| FY2024 | 2024-12-31 | (68.99M) | -18.4% |
| FY2023 | 2023-12-31 | (58.29M) | +7.6% |
| FY2022 | 2022-12-31 | (63.06M) | -93.0% |
| FY2021 | 2021-12-31 | (32.67M) | — |
Net Income vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +47.3% is the 2nd highest of 10, against a peer median of +23.7%.
- Net income amounts to 529.7% of revenue for JANX, versus a peer median of 160.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $309.06M USD | +37.6% | +32.1% | 275948.2% | |
| LTM Sep 2026 | $282.65M USD | +26.9% | +79.2% | — | |
| LTM Mar 2026 | $221.04M USD | +23.7% | — | — | |
| LTM Mar 2026 | €217.14M EUR | +906.0% | — | 582.2% | |
| LTM Mar 2026 | $153.6M USD | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $114.48M USD | +47.3% | +21.7% | 529.7% | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $68.17M USD | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $59.14M USD | -242.2% | -44.1% | 166.4% | |
| LTM Sep 2026 | $2.81M USD | -98.7% | -12.6% | 0.2% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | +23.7% | +17.0% | 160.3% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.91M | 17.2M | 20.01M | 33.02M | 40.22M |
| Change in Working Capital | 8.84M | 4.28M | (6.55M) | 685K | 6.71M |
| Accounts Receivables | 8M | 0 | 0 | 0 | 0 |
| Inventory | 831K | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | (294K) | 277K | 1.58M | 977K |
| Other Working Capital | (2.13M) | 4.57M | (6.83M) | (899K) | 5.74M |
| Other Non-Cash Items | (169K) | (2.18M) | (7.69M) | (10.59M) | (17.57M) |
| Operating Cash Flow | (16.98M) | (42.92M) | (50.58M) | (43.81M) | (82.24M) |
| Capital Expenditures | (1.48M) | (6.45M) | (1.85M) | (359K) | (1.04M) |
| Acquisitions (Net) | 339.48M | (64.71M) | 0 | 0 | 0 |
| Purchases of Investments | (473.63M) | (294.39M) | (317.34M) | (470.58M) | (705.22M) |
| Sales of Investments | 134.15M | 359.1M | 278M | 212.92M | 405.28M |
| Other Investing Activities | (339.48M) | 64.71M | 0 | 0 | 0 |
| Investing Cash Flow | (340.96M) | 58.27M | (41.19M) | (258.02M) | (300.98M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 204.17M | 500K | 56.53M | 698.27M | 5.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (347K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.81M | 0 | 3.02M | 14.97M | 0 |
| Financing Cash Flow | 386.52M | 500K | 59.55M | 713.24M | 4.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 28.59M | 15.84M | (32.22M) | 411.4M | (378.27M) |
| Free Cash Flow | (18.46M) | (49.37M) | (52.43M) | (44.17M) | (83.28M) |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.